Carolyn Blasdel, RN, FNP-BC, OCN
''Carolyn Blasdel began caring for patients with CML at the start of the Phase I Gleevec trial in 1998 at Oregon Health & Science University (OHSU) in Portland, Oregon, USA as a clinical research nurse with Dr. Brian Druker, MD. Her current practice focuses on side effect management, patient education, and promoting a high quality of life with excellent treatment outcomes for people living with CML.
She earned a Post-Master’s Certificate from Washington State University, Vancouver, Washington, her Master of Arts degree in Psychosocial Nursing at the University of Washington in Seattle, and her Bachelor of Science in Nursing at the University of Maryland in Baltimore. She is an Oncology Certified Nurse and is also board certified as a Family Nurse Practitioner by the American Nurses Credentialing Center.''
Extract of http://www.cmlsociety.org/?q=node/161
ARTICLES
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
February 29, 2012, PublMed
Therapeutic drug monitoring in CML patients on imatinib
September 1, 2007, Journal Blood
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
September 25, 2003, PublMed
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
February 29, 2012, PublMed
Therapeutic drug monitoring in CML patients on imatinib
September 1, 2007, Journal Blood
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
September 25, 2003, PublMed